• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·PFE
Held by 3 Gurus
Share

Pfizer Inc. Stocks

$ 24.37Last Updated 29.06.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 138.98B

$ 24.37
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Manager
Fund
Portfolio Weight (%)
Change
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Sign up, to see portfolios that hold this stock
Sign up, to see portfolios that hold this stock

Latest news

23.06.2026 15:45

Morning in New York: Chipmakers Drag Stock Indices Lower

23.06.2026 08:00

Pfizer's lung cancer drug trial has failed. What will happen to the stock?

22.06.2026 15:15

Morning in New York: Geopolitics Favors Buyers

06.02.2026 15:00

Agomab Therapeutics IPO: Pfizer and Sanofi-backed biotech starts trading

04.02.2026 15:45

Morning in New York: investors in search of a foothold

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Pfizer Inc. operates as a global biopharmaceutical enterprise, actively involved in the discovery, innovation, manufacturing, promotion, distribution, and sale of its pharmaceutical portfolio across the United States, Europe, and numerous international markets. The company’s comprehensive product range encompasses medicines and vaccines for a wide spectrum of therapeutic areas. These include treatments for cardiovascular and metabolic conditions, migraines, and women's health, exemplified by brands such as Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family. Pfizer also addresses infectious diseases with products like the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba, alongside its contributions to COVID-19 prevention and treatment, featuring Comirnaty and Paxlovid, and ongoing efforts in mRNA and antiviral technologies. Further offerings include biosimilars for chronic immune and inflammatory disorders, represented by Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo; and specialized medications for conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease, found under brands like the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin. The company also supplies sterile injectable and anti-infective medications, including Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga, in addition to a substantial oncology and specialty pipeline featuring biologics, small molecules, immunotherapies, and biosimilars like Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi. Additionally, Pfizer engages in contract manufacturing services. Its clientele is diverse, spanning wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical offices, and integrated healthcare delivery systems. The company maintains significant collaboration agreements with partners such as Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE. Pfizer Inc. was established in 1849 and has its corporate headquarters situated in New York, New York.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of PFE is 31 and suggests 25.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.07.2026 04:53

Shutterstock's stock plummeted nearly 30% after Getty Images called off its merger with the company

01.07.2026 02:13

Nike's earnings and revenue exceeded expectations. Why did its stock price fall?

01.07.2026 01:24

The Nasdaq had its best quarter since 2020, while the Dow posted its strongest first half in five years. What's next?

01.07.2026 00:45

The issuer of the USDC stablecoin has collapsed: Visa and Mastercard are creating a competing token

30.06.2026 23:40

Amazon will be the first among the cloud giants to invest $1 billion in its AI engineering division

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026